AnaptysBio Inc
Research AnaptysBio Inc (ANAB) on Bullrun: valuation model: 19.5% undervalued, market cap USD 1.37B, P/E 7.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANAB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal19.5% undervalued
- Market capUSD 1.37B
- P/E7.1
- Financial periodQ1 2026
- RevenueUSD 25.56M
- Net income-USD 52.88M
- Free cash flow-USD 25.94M
Valuation Snapshot
Bullrun's latest valuation model marks AnaptysBio Inc as 19.5% undervalued; latest market cap is USD 1.37B; P/E is 7.1.
Peer valuation comparison
Latest P/E is 7.13x versus a Healthcare sector median of 24.61x (71.0% below).
Latest P/E is 7.13x versus a United States median of 23.85x (70.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 234.60M | -USD 13.23M | USD 19.61M | n/a | -0.46 | USD 238.20M | USD 14.11M | USD 37.21M |
| FY2024 | USD 91.28M | -USD 145.23M | -USD 135.70M | n/a | -5.12 | USD 123.08M | USD 16.04M | USD 70.87M |
| FY2023 | USD 17.16M | -USD 163.62M | -USD 121.61M | n/a | -6.08 | USD 35.97M | USD 17.81M | USD 88.10M |
| FY2022 | USD 10.29M | -USD 128.72M | -USD 73.95M | n/a | -4.57 | USD 71.31M | USD 19.45M | USD 262.10M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.37B | 7.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 905.57M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 269.08M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 379.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 587.40M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 640.58M | n/a | n/a | n/a |
About AnaptysBio Inc
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is AnaptysBio Inc overvalued or undervalued?
Bullrun's valuation model currently marks AnaptysBio Inc as 19.5% undervalued.
What is AnaptysBio Inc's market cap?
AnaptysBio Inc's market capitalization is USD 1.37B.
What is AnaptysBio Inc's P/E ratio?
AnaptysBio Inc's price-to-earnings (P/E) ratio is 7.1.
What does AnaptysBio Inc do?
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis.